Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients

Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients

Show other versions (1)

<h4>Background</h4> The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for blockage by immunotherapy that uses the body’s own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evaluated t...

Full description

Bibliographic Details
Main Authors: Sebastian A. Omenai, Mustapha A. Ajani, Clement A. Okolo
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827435/?tool=EBI

Similar Items

Similar Items